Literature DB >> 18618714

Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.

Jennifer L Poitras1, Paola Dal Cin, Jon C Aster, Daniel J Deangelo, Cynthia C Morton.   

Abstract

Activating mutations in JAK2 are found in virtually all patients with polycythemia vera, and about half of those with essential thrombocythemia and primary myelofibrosis. In addition, less common aberrations (particularly gene fusions) involving JAK2 have been described in acute leukemias. With the advent of JAK2 inhibitor trials in myeloproliferative disorders, tumors with JAK2 mutations or rearrangements have become candidates for targeted therapy. In this report, we identify SSBP2 as a new JAK2 fusion partner in a patient with pre-B cell acute lymphocytic leukemia. This finding adds to the expanding compendium of JAK2 aberrations found in various hematopoietic malignancies, as well as the potential need for a diagnostic FISH analysis in the appropriate clinical setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618714     DOI: 10.1002/gcc.20585

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  25 in total

Review 1.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

2.  PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Authors:  Wenbin Xiao; Maheetha Bharadwaj; Max Levine; Noushin Farnhoud; Friederike Pastore; Bartlomiej M Getta; Anne Hultquist; Christopher Famulare; Juan S Medina; Minal A Patel; Qi Gao; Natasha Lewis; Janine Pichardo; Jeeyeon Baik; Brian Shaffer; Sergio Giralt; Raajit Rampal; Sean Devlin; Robert Cimera; Yanming Zhang; Maria E Arcila; Elli Papaemmanuil; Ross L Levine; Mikhail Roshal
Journal:  Blood Adv       Date:  2018-12-11

3.  SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability.

Authors:  Y Wang; S Klumpp; H M Amin; H Liang; J Li; Z Estrov; P Zweidler-McKay; S J Brandt; A Agulnick; L Nagarajan
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

4.  Crystal structure of the LUFS domain of human single-stranded DNA binding Protein 2 (SSBP2).

Authors:  Hongyang Wang; Zhizhi Wang; Qun Tang; Xiao-Xue Yan; Wenqing Xu
Journal:  Protein Sci       Date:  2019-02-12       Impact factor: 6.725

5.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

Review 6.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

7.  Cigarette smoke induces promoter methylation of single-stranded DNA-binding protein 2 in human esophageal squamous cell carcinoma.

Authors:  Yiping Huang; Xiaofei Chang; Juna Lee; Yong Gu Cho; Xiaoli Zhong; Il-Seok Park; Jun-Wei Liu; Joseph A Califano; Edward A Ratovitski; David Sidransky; Myoung Sook Kim
Journal:  Int J Cancer       Date:  2011-05-15       Impact factor: 7.396

8.  The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.

Authors:  Dagmar Schinnerl; Klaus Fortschegger; Maximilian Kauer; João R M Marchante; Reinhard Kofler; Monique L Den Boer; Sabine Strehl
Journal:  Blood       Date:  2014-12-16       Impact factor: 22.113

9.  A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.

Authors:  Shashidhar S Jatiani; Stephen C Cosenza; M V Ramana Reddy; Ji Hee Ha; Stacey J Baker; Ajoy K Samanta; Matthew J Olnes; Loretta Pfannes; Elaine M Sloand; Ralph B Arlinghaus; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-04

10.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Authors:  Kathryn G Roberts; Yongjin Li; Debbie Payne-Turner; Richard C Harvey; Yung-Li Yang; Deqing Pei; Kelly McCastlain; Li Ding; Charles Lu; Guangchun Song; Jing Ma; Jared Becksfort; Michael Rusch; Shann-Ching Chen; John Easton; Jinjun Cheng; Kristy Boggs; Natalia Santiago-Morales; Ilaria Iacobucci; Robert S Fulton; Ji Wen; Marcus Valentine; Cheng Cheng; Steven W Paugh; Meenakshi Devidas; I-Ming Chen; Shalini Reshmi; Amy Smith; Erin Hedlund; Pankaj Gupta; Panduka Nagahawatte; Gang Wu; Xiang Chen; Donald Yergeau; Bhavin Vadodaria; Heather Mulder; Naomi J Winick; Eric C Larsen; William L Carroll; Nyla A Heerema; Andrew J Carroll; Guy Grayson; Sarah K Tasian; Andrew S Moore; Frank Keller; Melissa Frei-Jones; James A Whitlock; Elizabeth A Raetz; Deborah L White; Timothy P Hughes; Jaime M Guidry Auvil; Malcolm A Smith; Guido Marcucci; Clara D Bloomfield; Krzysztof Mrózek; Jessica Kohlschmidt; Wendy Stock; Steven M Kornblau; Marina Konopleva; Elisabeth Paietta; Ching-Hon Pui; Sima Jeha; Mary V Relling; William E Evans; Daniela S Gerhard; Julie M Gastier-Foster; Elaine Mardis; Richard K Wilson; Mignon L Loh; James R Downing; Stephen P Hunger; Cheryl L Willman; Jinghui Zhang; Charles G Mullighan
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.